Jean-François Korobelnik, Paolo Lanzetta, Sergio Leal, Frank G Holz, W Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J Berliner, Andrea Schulze, Min Zhao, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Peter Morgan-Warren, Zoran Hasanbasic, Robert Vitti, Karen W Chu, Kimberly Reed, Rafia Bhore, Yenchieh Cheng, Zhanying Bai, Boaz Hirshberg, George D Yancopoulos, Tien Y Wong, PULSAR Investigators
چکیده
To report the efficacy, durability, and safety of intravitreal aflibercept 8 mg versus intravitreal aflibercept 2 mg every 8 weeks (2q8) in patients with neovascular age-related macular degeneration (nAMD) through 96 weeks, PULSAR (ClinicalTrials.gov identifier, NCT04423718). Phase 3, randomized,…
متن کامل چکیده در سایت ناشر در دسترس است.